Free Trial
→ No. 1 stock to cash in on the death of iPhone (From Stansberry Research) (Ad)tc pixel
NASDAQ:PMCB

Nuvilex Q4 2025 Earnings Results & Report

Nuvilex logo
$0.41 +0.01 (+2.16%)
As of 10/9/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Nuvilex reported Q4 2025 earnings on August 8, 2025. The company reported EPS of -$0.25.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes

Nuvilex EPS Results

Actual EPS
-$0.25
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nuvilex Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Nuvilex's next earnings date is estimated for Wednesday, December 16, 2026, based on past reporting schedules.

Conference Call Resources

Nuvilex Q4 2025 Earnings FAQ

Nuvilex (NASDAQ:PMCB) reported earnings of -$0.25 per share for Q4 2025. The report was announced on Friday, August 8, 2025.

Nuvilex's next earnings date is estimated for Wednesday, December 16, 2026. MarketBeat tracks confirmed and estimated earnings dates for Nuvilex on the company's earnings history page.

Nuvilex Earnings Headlines

Nuvilex (NASDAQ:PMCB) Shares Down 2.5% - Here's Why
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31090161
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
September 2, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250902025594/en/pharmacyte-biotech-inc.-increases-stake-in-tnf-pharmaceuticals-around-recent-license-for-breakthrough-light-speed-computing-platform-for-use-in-cryptocurrency-applications/
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this supercycle - and says that may be conservative. Billionaire Pierre Lassonde has argued for $19,000. Former CIA advisor Jim Rickards targets $27,000 based on a federal revaluation of the gold supply. But the bigger opportunity may not be gold itself. A 'backdoor' gold-linked asset has historically multiplied gold's move by 10x or more - returning 846%, 1,668%, 1,847%, and 1,915% in the last supercycle.tc pixel
 |  Traders Agency (Ad)
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
August 20, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250820055624/en/PharmaCyte-Biotech-Inc.-Announces-Closing-of-7-Million-Financing/
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
August 18, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250818528622/en/pharmacyte-biotech-inc.-announces-7-million-capital-raise-led-by-existing-investors/
MyMD Pharmaceuticals Secures Strategic Investments
May 21, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20240521024499/en/mymd-pharmaceuticals-secures-strategic-investments/
See More Nuvilex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvilex and other key companies, straight to your email.

About Nuvilex

Nuvilex (NASDAQ:PMCB), Inc. was a biotechnology company that developed therapies for cancer and other serious diseases. The company focused on combining cellular therapy with drug-delivery technologies intended to provide localized treatment while limiting exposure to healthy tissue.

Its principal program involved the Cell-in-a-Box technology, which uses encapsulated genetically engineered cells to convert certain chemotherapy prodrugs into active cancer-fighting compounds at or near a tumor. Nuvilex applied this approach primarily to pancreatic cancer, including a planned treatment regimen involving encapsulated cells and ifosfamide.

Nuvilex later changed its name to PharmaCyte Biotech, Inc. and continued development of the Cell-in-a-Box platform under the PharmaCyte Biotech name. Publicly available information about Nuvilex’s operations, geographic reach, and leadership is primarily historical because the company no longer operates under the Nuvilex name.

View Nuvilex Profile
Earnings Tools